Personalis, Inc., a leading provider of genome-based diagnostics,
announced today that its onsite clinical laboratory has received
accreditation from the College of American Pathologists (CAP), meeting
the highest standard of excellence in clinical laboratory practices.
With this accreditation, Personalis, Inc. joins an elite group of
globally recognized facilities that operate at the highest level of
quality laboratory standards.
The CAP Laboratory Accreditation Program is a globally recognized
program that utilizes teams of highly specialized laboratory
professionals as inspectors. During the accreditation process,
inspectors meticulously examine the clinical laboratory's records and
quality control procedures. They also assess the laboratory's staff
qualifications, equipment, facilities, safety program, and overall
management to ensure it meets CAP's diverse and stringent requirements.
The goal of the CAP program is to improve patient safety by advancing
the quality of pathology and laboratory services through education and
"We strive to provide quality service in every aspect of what we deliver
to our customers," said John West, Personalis' CEO. "We feel that
holding ourselves to the highest standards of laboratory practice is an
integral part of our operations. With sevices such as our ACE Clinical
Exome™, we are trying to find answers to the most difficult clinical
cases. We are committed to providing the most accurate and thorough
results possible to our customers, so they can provide the best possible
care for their patients."
About the College of American Pathologists
The College of American Pathologists (CAP), celebrating 50 years as the
gold standard in laboratory accreditation, is a medical society that
serves more than 18,000 physician members and the global laboratory
community. It is the world's largest association composed exclusively of
board-certified pathologists and is the worldwide leader in laboratory
quality assurance. The College advocates accountable, high-quality, and
cost-effective patient care.
More information about the CAP can be found at www.cap.org.
About Personalis, Inc.
Personalis, Inc. provides researchers and clinicians accurate DNA
sequencing and interpretation of human exomes and genomes. We support
researchers engaging in case-control, family-based, or proband-only
genomic studies of disease, pharmacogenomics, and cancer. Our ACE
(Accuracy and Content Enhanced) Technology supplements a standard exome
or genome, substantially increasing its medically-relevant coverage and
accuracy. Personalis builds on this enhanced sequencing foundation with
innovative algorithms and proprietary databases for alignment, variant
calling, annotation, and analysis. Through this comprehensive approach,
we provide genomic data and interpretation of the highest accuracy.
Personalis' ACE Clinical Exome™ has several major features that are not
addressed by standard exome sequencing platforms: a high level of gene
finishing, structural variant detection, and inclusion of non-exonic
interpretable content. The ACE Clinical Exome™ has been specifically
designed to enhance diagnostic yield for clinical care.
For more information about Personalis, Inc., please visit www.personalis.com.
[ Back To NFVZone's Homepage ]